Contact our team
Need Help, Contact us
Where therapeutic progress is made
Driving specialty neurology forward
Merz Therapeutics’ R&D and production activities are the foundations of our leadership in specialty neurology.
We work tirelessly to develop new treatments through in-house clinical development and supporting the research of others. Meanwhile we work constantly to grow the indications and availability of our existing portfolio.
Our research facility in Frankfurt, Germany, accommodates 150 colleagues. In addition, we operate four production sites – two internal and two external. These sites bring together colleagues from all around the globe, all working closely to discover, develop, and deliver therapeutics for specialty neurology conditions.
Our expertise
Our team contains world-class expertise across multiple essential disciplines, including:
R&D is also responsible for managing over 800 product licenses in over 80 countries.
Pre-clinical sciences and toxicology
Botulinum Neurotoxin biotechnology and formulation development
Clinical sciences and operations, biometrics, contract research organization management
Clinical trial supply
(Phase II-IV)
Global regulatory affairs
Global product safety / pharmacovigilance
Project management
Good practice quality assurance
Life cycle management / product maintenance
Inhaled administration of levodopa
At Merz Therapeutics, we are committed to innovation by unlocking the full potential of established medicines for the good of patients. One example of this is the inhaled administration of levodopa using our patented Arcus® delivery system. When taken orally, levodopa absorption can vary greatly due to factors such as the timing of meals and the type of food consumed. Our inhaler for levodopa avoids this variability, making on-demand use a possibility for patients who need it.
XTRACT TechnologyTM for a purer therapeutic product
Merz Therapeutics has developed XTRACTTM, a unique manufacturing process for botulinum toxin that utilizes chromatography to remove complexing proteins, thereby leaving only the active therapeutic product and minimizing waning efficacy due to immunogenicity.
Medical affairs excellence
Our Medical Affairs work is a bridge between patients, physicians and us. We are committed to healthcare provision “beyond the product”.
Merz Therapeutics provides clear and current medical information and education for all our products, and keeps that information aligned to customers’ changing needs.
We constantly ask our customers and patients what they need, and adapt our programs in response.
In 2023-2024 we:
Organised 13 advisory boards
Submitted 56 poster abstracts
Submitted 9 publications
Trained 811 HCPs across 15 events
Organised 7 medical education programs
Includes:
Engaging stakeholders to understand their evolving needs – for example through advisory boards
Developing medical education & information tailored to those needs - for example current Botulinum Toxin injection training for healthcare professionals
Patient advocacy
Real-world evidence generation - for example observational or phase 4 studies
Engagement with younger healthcare professionals in specialty neurology, to support their professional and knowledge development
